CytomX Therapeutics Inc Cash Flow-to-Debt Ratio
CytomX Therapeutics Inc cash flow-to-debt ratio. CytomX Therapeutics Inc (CTMX) has a Cash Flow-to-Debt Ratio of -0.23x as of June 2026, meaning its operating cash flow of $-18.07 Million could theoretically repay 0% of its total liabilities ($79.16 Million) in one year. Check CTMX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CytomX Therapeutics Inc (2013–2025)
Cash flow-to-debt ratio of CytomX Therapeutics Inc from 2013 to 2025. Historical debt coverage capacity for CytomX Therapeutics Inc across 13 annual periods. Check CytomX Therapeutics Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CytomX Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2013–2025)
CytomX Therapeutics Inc cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for CytomX Therapeutics Inc. For the full cash flow conversion analysis, see CytomX Therapeutics Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.44x | $-75.59 Million | $52.56 Million | ▼ -101.8% |
| 2024 | -0.71x | $-86.23 Million | $120.99 Million | ▼ -217.0% |
| 2023 | -0.22x | $-56.03 Million | $249.24 Million | ▲ +29.7% |
| 2022 | -0.32x | $-110.79 Million | $346.64 Million | ▲ +32.9% |
| 2021 | -0.48x | $-119.03 Million | $250.03 Million | ▼ -3417.1% |
| 2020 | 0.01x | $5.26 Million | $366.44 Million | ▲ +103.0% |
| 2019 | -0.48x | $-140.48 Million | $290.17 Million | ▼ -109.1% |
| 2018 | -0.23x | $-75.52 Million | $326.23 Million | ▼ -144.5% |
| 2017 | 0.52x | $170.37 Million | $327.75 Million | ▲ +3186.5% |
| 2016 | -0.02x | $-2.03 Million | $120.65 Million | ▲ +95.6% |
| 2015 | -0.39x | $-27.41 Million | $71.15 Million | ▼ -283.7% |
| 2014 | 0.21x | $31.80 Million | $151.60 Million | ▲ +253.1% |
| 2013 | -0.14x | $-8.01 Million | $58.46 Million | — |